Who is sponsoring NCT04728633?

NCT04728633 is sponsored by Thomas Jefferson University.

What drugs are being tested in NCT04728633?

Interventions in NCT04728633: Carmustine, Ethiodized Oil, Transarterial Chemoembolization, Medical Device Usage and Evaluation.

What condition does NCT04728633 study?

NCT04728633 studies Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Choroidal and Ciliary Body Melanoma AJCC V8.

Is NCT04728633 still recruiting?

NCT04728633 is currently active, enrolled. Last updated 6 August 2025.

Last reviewed 2025-08-06 · How we verify

NCT04728633

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases

Active, enrolled Phase 2 Last updated 6 August 2025

What this trial tests

Phase 2 trial testing Carmustine in Metastatic Malignant Neoplasm in the Liver in 28 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

27 September 2021

Primary endpoint
31 January 2027

30 June 2027

Quick facts

Lead sponsor	Thomas Jefferson University
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	28
Start date	27 September 2021
Primary completion	31 January 2027
Estimated completion	30 June 2027
Sites	1 location across United States

Drugs / interventions tested

Carmustine (CARMUSTINE) — full drug profile →
Ethiodized Oil — full drug profile →
Transarterial Chemoembolization — full drug profile →
Medical Device Usage and Evaluation

Conditions studied

Metastatic Malignant Neoplasm in the Liver — all drugs for Metastatic Malignant Neoplasm in the Liver →
Metastatic Uveal Melanoma — all drugs for Metastatic Uveal Melanoma →
Stage IV Choroidal and Ciliary Body Melanoma AJCC V8 — all drugs for Stage IV Choroidal and Ciliary Body Melanoma AJCC V8 →

Sponsor

Thomas Jefferson University

Who can join

18 and older, any sex, with Metastatic Malignant Neoplasm in the Liver or Metastatic Uveal Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial studies the effect of transarterial chemoembolization in treating patients with uveal melanoma that has spread to the liver (liver metastases). Transarterial chemoembolization involves the injection of a blocking agent (gelatin sponge, ethiodized oil) and a chemotherapy agent (carmustine) directly into the artery in the liver to treat liver cancers. Chemotherapy drugs, such as carmustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. transarterial chemoembolization with carmustine in combination with ethiodized oil and gelatin sponge may help cause the tumors in the liver to shrink or disappear.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Poor Response to Checkpoint Immunotherapy in Uveal Melanoma Highlights the Persistent Need for Innovative Regional Therapy Approaches to Manage Liver Metastases.
Szeligo BM, Ivey AD, Boone BA. · · 2021 · cited 18× · PMID 34298647 · DOI 10.3390/cancers13143426
How we treat patients with metastatic uveal melanoma.
Saldanha EF, Ribeiro MF, Hirsch I, Spreafico A, et al · · 2025 · cited 7× · PMID 40112696 · DOI 10.1016/j.esmoop.2025.104496
From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma.
Synoradzki KJ, Paduszyńska N, Solnik M, Toro MD, et al · · 2024 · cited 7× · PMID 38392052 · DOI 10.3390/curroncol31020058
Chemoembolization Beyond Hepatocellular Carcinoma: What Tumors Can We Treat and When?
DePietro DM, Li X, Shamimi-Noori SM. · · 2024 · cited 2× · PMID 38495263 · DOI 10.1055/s-0043-1777716

Verify or expand the search:

Other trials of Carmustine

Trials testing the same drug.

NCT06687772 — CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant · Phase 2 · recruiting
NCT06692452 — Tazemetostat Plus CHOP in 1L T-cell Lymphoma · Phase 2 · withdrawn
NCT06377540 — MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma · Phase 2 · recruiting
NCT05863845 — Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL · NA · unknown
NCT05521984 — Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SG · Phase 1 · recruiting

Other recruiting trials for Metastatic Malignant Neoplasm in the Liver

Currently open trials in the same condition.

NCT06016855 — Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroend · Phase 4 · recruiting
NCT05863195 — Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Pa · Phase 3 · recruiting
NCT05039632 — Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (An · Phase 1, PHASE2 · recruiting
NCT05791448 — AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease · Phase 1 · recruiting
NCT05040360 — Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors · Phase 2 · recruiting

Other Thomas Jefferson University trials

Trials by the same sponsor.

NCT07526480 — Improving Dementia Care in Primary Practice · NA · not yet recruiting
NCT07414550 — Radiotherapy for Refractory Hidradenitis Suppurativa · NA · not yet recruiting
NCT07402018 — Intra-aortic Balloon Counterpulsation (IABC) Compliance · recruiting
NCT07217197 — Respiratory Monitoring System That Detects & Predicts OIRD · NA · enrolling by invitation
NCT07145099 — The IMPACT Study: Personalized Physical Therapy for Better Recovery and a Stronger Core After Hernia Surgery · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04728633 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Thomas Jefferson University
Last refreshed: 6 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04728633.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing